Standard vs. Accelerated Initiation of RRT in Acute Kidney Injury (STARRT-AKI: Principal Trial)

NCT02568722 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3019

Last updated 2024-10-18

Study results available
· View outcomes & findings →

Summary

The objectives of this trial are to determine whether, in critically ill patients with severe acute kidney injury (AKI), randomization to accelerated initiation of renal replacement therapy (RRT), compared to standard initiation, leads to:

1. Improved survival (primary outcome); and
2. Recovery of kidney function (principal secondary outcome), defined as independence from RRT at 90 days

Conditions

Interventions

OTHER

Standard RRT initiation

In the absence of kidney function recovery, the initiation of RRT will be permitted if one of the following develops: serum potassium ≥ 6.0 mmol/L; pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L; evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload; and/or persistent AKI \> 72 hours following the time of randomization.

OTHER

Accelerated RRT initiation

A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV
  • National Health and Medical Research Council, Australia

    collaborator OTHER
  • Baxter Healthcare Corporation

    collaborator INDUSTRY
  • The George Institute

    collaborator OTHER
  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV
  • Medical Research Institute of New Zealand

    collaborator OTHER
  • Health Research Council, New Zealand

    collaborator OTHER
  • Unity Health Toronto

    lead OTHER

Principal Investigators

  • Ron Wald, MDCM MPH · Unity Health Toronto

  • Sean M Bagshaw, MD MSc · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • China
  • Finland
  • France
  • Germany
  • Ireland
  • Italy
  • New Zealand
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02568722 on ClinicalTrials.gov